In our study, we found that down-regulation of TAB2 enhanced the sensitivity of A549/DDP cells and we proposed that TAB2 might play a vital role in drug resistance to chemotherapy and targeted therapy in NSCLC. This evidence concerns the gene TAB2 and non-small cell lung carcinoma.